Clarus Therapeutics, which has been moving ahead with venture cash from the likes of Thomas McNerney and H.I.G. BioVentures, has brushed off its IPO pitch designed to back the launch of a new drug for low testosterone which is now under regulatory review.

…read more

Source: Clarus dusts off an $86M IPO as it preps launch of low-T treatment


0 No comments